Extended Data Fig. 2: Antitumour efficacy. | Nature Biomedical Engineering

Extended Data Fig. 2: Antitumour efficacy.

From: Activatable near-infrared probes for the detection of specific populations of tumour-infiltrating leukocytes in vivo and in urine

Extended Data Fig. 2: Antitumour efficacy.

Tumour growth curves (n = 6) of (a) 4T1 tumour-bearing mice and (b) CT26 tumour-bearing mice. For 4T1 tumour-bearing mice: aPD-L1 versus saline: P = 0.0005; Oxa versus saline: P < 0.0001; aPD-L1/Oxa versus saline: P < 0.0001. For CT26 tumour-bearing mice: aPD-L1 versus saline: P < 0.0001; aCD47 versus saline: P = 0.0002; aPD-L1/aCD47 versus saline: P < 0.0001. Body weights curves of (c) 4T1 tumour-bearing mice and (d) CT26 tumour-bearing mice. Overall survival curves (n = 6) of (e) 4T1 tumour-bearing mice and (f) CT26 tumour-bearing mice. For 4T1 tumour-bearing mice, aPD-L1/Oxa versus saline: P = 0.0008. For CT26 tumour-bearing mice, aPD-L1/aCD47 versus saline: P = 0.0005. 4T1 tumour-bearing mice were intraperitoneally injected with saline, Oxa (6 mg/kg), aPD-L1 (10 mg/kg) and aPD-L1/Oxa at day 0, 2 and 4. CT26 tumour-bearing mice were intraperitoneally injected with saline, aCD47 (10 mg/kg), aPD-L1 (10 mg/kg) and aPD-L1/aCD47 at day 0, 2 and 4.

Source data

Back to article page